HPV vaccine: Current status and future directions

Medical Journal Armed Forces India

Volumn 71, Issue 2, 2015, Pages 171-177

  Sushil Kumar, Surg Vice Admiral ^a   Manash Biswas, Brig ^a   Jose, Tony ^a  

^a ARMED FORCES MEDICAL COLLEGE   (India)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Humoral immune response; Papillomavirus vaccines; Viral like particles

Indexed keywords

APIGENIN; BACTERIAL VECTOR; DNA; HEAT SHOCK PROTEIN 70; INTERLEUKIN 2; LISTERIOLYSIN O; PROTEIN E6; PROTEIN E7; PROTEIN L1; PROTEIN L2; UNCLASSIFIED DRUG; VERPASEP CALTESPEN; VIRUS PROTEIN; VIRUS VECTOR; WART VIRUS VACCINE;

AGE; ARTICLE; COST BENEFIT ANALYSIS; DENDRITIC CELL; DRUG COST; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. LACTIS; MORTALITY; MULTIPLE SCLEROSIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PROTEIN EXPRESSION; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS LIKE AGENT; VIRUS TITRATION;

EID: 84930721213     PISSN: 03771237     EISSN: 22134743     Source Type: Journal    
DOI: 10.1016/j.mjafi.2015.02.006     Document Type: Review

References (30)

1. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607-615.
2. Walboomers JM, Meijer CJ. Do HPV-negative cervical carcinomas exist. J Pathol. 1997;181:253-254.
3. World Health Organization. Human Papillomavirus Vaccines. WHO position paper. Weekly Epidemiological Record 2009. vol. 84. 2009:118-131.
4. World Health Organization. The Immunological Basis for Immunization Series. Module 19: Human Papillomavirus Infection. WHO, Department of Immunization, Vaccines and Biologicals; 2011.
5. de Villiers E-M. Cross-roads in the classification of papillomaviruses. Virology. 2013;445:2-10.
6. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111:145-153.
7. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
8. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccinesdimmune responses. Vaccine. 2012;30(suppl 5):F83-F87.
9. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009;9:347-356.
10. Roden RBS, Ling M, Wu T-C. Vaccination to prevent and treat cervical cancer. Hum Pathol. 2004;35:971-982.
11. Dillner J, Kjaer SK, Wheeler CM, et al. On behalf of FUTURE I/II Study Group. Four years efficacy of prophylactic human papillomavirus quadrivalent vaccine against lowgrade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial. BMJ. 2010;341:c3493.
12. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and pre-cancer caused by oncogenic HPV types (PATRICIA):final analysis of a double-blind, randomized study in young women. Lancet. 2009;374:301-314.
13. Herrero R, Wacholder S, Rodrigeuz AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vac-cine: a community-based randomised clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1:408-419.
14. McKeage K, Romanowski B. AS04-adjuvanted human papillomavirus (HPV)types 16 and 18 vaccine (Cervarix(R)): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs. 2011;71:465-488.
15. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30S:F123-F138.
16. Dillner J, Arbyn M, Unger E, Dillner L. Monitoring of human papillomavirus vaccination. Clin Exp Immunol. 2011;163:17-25.
17. Franceschi S, Denny L, Irwin KL, et al. EUROGIN 2010 roadmap on cervical cancer prevention. Int J Cancer. 2011;128:2765-2774.
18. Skinner SR, Szarewski A, Romanowski B, et al, VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384:2213-2227. http://dx.doi.org/10.1016/S0140-6736(14)60920-X.
19. Tota JE, Ramanakumar AV, Jiang M, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol. 2013;178:625-634.
20. Palefsky Joel M. Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health. 2010 April;46(4 suppl l):S12-S19.
21. Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJLM, Berkhof J, Wallinga J. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med 8(12): e1001147. doi:10.1371/journal.pmed.1001147.
22. WHO Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination. Extract from report of GACVS meeting of 11-12 December 2013, published in the WHO Weekly Epidemiological Record on 14 February 2014.
23. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7:38.
24. Karanam B, Jagu S, Huh WK, Roden RBS. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009;87:287-299.
25. Fraillery D, Baud D, Pang SY, et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol. 2007;14:1285-1295 [PubMed: 17687110].
26. Barbara M, Bharat M, Nam PT, et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2012;17:469-492.
27. Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8:421-439.
28. Lin K, Roosinovich E, Ma B, et al. Therapeutic HPV DNA vaccines. Immunol Res. 2010;47:86-112.
29. Lin J, Xu J, Albers AE, et al. New developments in therapeutic HPV vaccines. Curr Obstet Gynecol Rep. 2012;1:106-115.
30. Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dosetrial. J Virol. 2008;82:1968-1979.